DIRECT TO LUNGS
WHY TYVASO?
SO
you can treat at the site of disease2,3
TYVASO is a direct-to-the-lungs, inhaled prostacyclin mimetic indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3).2
How TYVASO works2,3
- TYVASO is delivered directly to the lungs, which are highly vascularized, providing an enormous surface area for drug absorption and an attractive target for drug delivery2-5
- TYVASO is inhaled directly to distal airspaces that are in close proximity to pulmonary arterioles affected by PH6
Direct-to-lung delivery results in higher concentrations in the pulmonary arterial vasculature, which may selectively enhance blood flow for better ventilation and perfusion matching with less off-target exposure.3
TYVASO has 2 delivery device options:
- A low-effort, maintenance-free dry powder inhaler that utilizes a normal, deep breath7,8
- An ultrasonic nebulizer that utilizes normal patient breathing and is not dependent on lung capacity2,9
WHO=World Health Organization.
The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.